Eiger BioPharmaceuticals Stock
Stocks
EIGR
US28249U2042
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.500 USD | -.--% |
|
-.--% | - |
| 01/10/24 | Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect | CI |
| 30/09/24 | Eiger BioPharmaceuticals, Inc. Went Out of Business | CI |
| Market Cap | 12.59M 10.86M 9.98M 9.4M 17.66M 1.19B 17.81M 118M 46.06M 583M 47.24M 46.23M 2.02B | P/E 2022 |
-0.51x | P/E 2023 | -0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 27.95M 24.11M 22.17M 20.86M 39.2M 2.64B 39.53M 263M 102M 1.29B 105M 103M 4.48B | EV / Sales 2022 |
-836,796x | EV / Sales 2023 | 1,605,487x |
| Free-Float |
86.47% | Yield 2022 * |
-
| Yield 2023 | - |
| 3 years | 1.1 | 29.07 | |
| 5 years | 1.1 | 300.64 | |
| 10 years | 1.1 | 618.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 59 | 18/04/2022 | |
Douglas Staut
PRN | Corporate Officer/Principal | - | 19/04/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 31/10/23 | Propel Bio Management LLC
| Buy | Company | 24,332 | 0.0549% | |
| 31/10/23 | Propel Bio Management LLC
| Buy | Company | 278,239 | 0.6281% | |
| 18/10/23 | Propel Bio Management LLC
| Other | Company | 5,096,986 | 11.5065% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | -.--% | -70.51% | 12.59M | ||
| -0.22% | -1.14% | -11.88% | -13.09% | 43.51B | ||
| +0.76% | +9.42% | +303.09% | +540.82% | 33.29B | ||
| -4.74% | -6.31% | +10.75% | -20.99% | 29.9B | ||
| -0.47% | -0.35% | +3.38% | +31.20% | 29.34B | ||
| +0.06% | +4.36% | +13.31% | +21.11% | 25.42B | ||
| -0.02% | +10.18% | - | - | 14.36B | ||
| -0.98% | -1.86% | +53.43% | +106.06% | 13.18B | ||
| -0.29% | -4.40% | +3.13% | +1.69% | 12.72B | ||
| +1.67% | +1.35% | +105.56% | +81.16% | 12.08B | ||
| Average | -0.42% | +1.19% | +53.42% | +75.27% | 21.38B | |
| Weighted average by Cap. | -0.63% | +1.29% | +61.92% | +103.57% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 13.48 11.63 10.69 10.07 18.92 1.27K 19.07 126.74 49.34 624.54 50.61 49.53 2.16K | 15.77 13.61 12.51 11.78 22.13 1.49K 22.31 148.26 57.72 730.56 59.2 57.93 2.53K |
| Net income | -96.78M -83.49M -76.76M -72.25M -136M -9.13B -137M -910M -354M -4.48B -363M -355M -15.51B | -74.96M -64.67M -59.46M -55.96M -105M -7.07B -106M -705M -274M -3.47B -281M -275M -12.01B |
| Net Debt | -63.29M -54.6M -50.2M -47.25M -88.79M -5.97B -89.53M -595M -232M -2.93B -238M -232M -10.14B | 15.36M 13.25M 12.18M 11.47M 21.55M 1.45B 21.73M 144M 56.2M 711M 57.65M 56.41M 2.46B |
Employees
25
- Stock Market
- Stocks
- EIGR Stock
Select your edition
All financial news and data tailored to specific country editions
















